Related references
Note: Only part of the references are listed.Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Cilofexor, a NonsteroidalFXRAgonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial
Keyur Patel et al.
HEPATOLOGY (2020)
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials
Stephen A. Harrison et al.
JOURNAL OF HEPATOLOGY (2020)
Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances
Keisaku Sato et al.
HEPATOLOGY (2019)
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
Arun J. Sanyal et al.
HEPATOLOGY (2019)
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials
Quentin M. Anstee et al.
HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Acetyl-CoA carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
Eric J. Lawitz et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
Stephen A. Harrison et al.
GASTROENTEROLOGY (2018)
Acetyl-CoA Carboxylase Inhibition Reverses NAFLD and Hepatic Insulin Resistance but Promotes Hypertriglyceridemia in Rodents
Leigh Goedeke et al.
HEPATOLOGY (2018)
Combination of an FXR agonist and an ACC inhibitor increases anti-fibrotic efficacy in rodent models of NASH
J. Bates et al.
JOURNAL OF HEPATOLOGY (2018)
FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
Romeo Papazyan et al.
JOURNAL OF LIPID RESEARCH (2018)
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease
Rohit Loomba et al.
GASTROENTEROLOGY (2018)
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman et al.
GUT (2017)
Acetyl-Coenzyme A Carboxylase Inhibition Reduces De Novo Lipogenesis in Overweight Male Subjects: A Randomized, Double-Blind, Crossover Study
Kathryn Stiede et al.
HEPATOLOGY (2017)
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation
Chai-Wan Kim et al.
CELL METABOLISM (2017)
Global Epidemiology of Nonalcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes
Zobair M. Younossi et al.
HEPATOLOGY (2016)
The Hierarchical Model of NAFLD: Prognostic Significance of Histologic Features in NASH
Rohit Loomba et al.
GASTROENTEROLOGY (2015)
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease
Paul Angulo et al.
GASTROENTEROLOGY (2015)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
The Portal Inflammatory Infiltrate and Ductular Reaction in Human Nonalcoholic Fatty Liver Disease
Victoria L. Gadd et al.
HEPATOLOGY (2014)
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
T Inagaki et al.
CELL METABOLISM (2005)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Share Paper
